Clinigen to distribute BioQ's pain relief drug in Europe

AIM-listed pharmaceutical Clinigen is to distribute BioQ Pharma’s post-surgery pain management drug, Ropivacaine Readyfusor.

The company’s subsidiary Idis Global Access has agreed to supply and distribute the pre-filled Ropivacaine Readyfusor for post-operative pain management in Europe, apart from France and Germany.

Idis will make the Ropivacaine Readyfusor available before it has received national marketing authorisation on an on-demand basis to physicians and pharmacists in the UK, while it will also provide the product to other European territories before approval.

Ropivacaine Readyfusor is pre-filled by the manufacturer with 0.2% Ropivacaine, a non-narcotic local anaesthetic, for delivery at the point of care activated by a single touch for pain relief for at least 48 hours after surgery.

Steve Glass, Clinigen’s chief commercial officer for North America and Europe, said: "This partnership with BioQ Pharma marks another important supply agreement for Idis GA. It demonstrates the continuing demand from pharmacists and physicians for a compliant route to obtain medicines that are unlicensed or unavailable in their country. There is also an increase in engagement from manufacturers to work with us to help provide continuous access to their products, to better serve patients with unmet medical needs."

Shares in Clinigen were down 0.47% to 713.64p at 1037 GMT.